Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 5/31/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Christophe Baudouin?

Christophe Baudouin

Professor and Chair of Ophthalmology

Quinze-Vingts National Ophthalmology Hospital

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Web References(42 Total References)


Mednet - CME, CHE | New Data for the Comprehensive Management of Glaucoma

www.mednet.ca [cached]

"We must try to use unpreserved medications as much as possible," stressed Dr. Christophe Baudouin, Quinze-Vingts National Ophthalmology Hospital, Paris, France.
"Subclinical inflammation develops in about 80% of patients on long-term topical treatment, especially those on multiple drug regimens, and the preservative is the cause in 90% of cases." Most anti-glaucoma medications contain benzalkonium chloride as a preservative, which has consistently demonstrated toxic effects in laboratory, experimental and clinical studies, he reminded delegates. It has been shown to be associated with tear film instability, loss of goblet cells, conjunctival squamous metaplasia and apoptosis, disruption of the corneal epithelium barrier, loss of endothelial cells if introduced into the anterior chamber, and even blood-aqueous barrier disruption in the early phase of pseudophakia. "Moreover, long-term topical drug use can induce ocular surface changes, inflammation and subconjunctival fibrosis, corneal surface impairment and failure of glaucoma surgery, which in most cases are direct toxic effects far from being allergic reactions as has been proposed. Such adverse effects have a negative impact on compliance," Dr. Baudouin noted.


www.opiatech.com

The EYEPRIM™ device is based on an original idea, suggested by Christophe Baudouin, MD, PhD, Chairman of Department of Ophthalmology III at Quinze-Vingts Hospital and Research team leader at the Vision Institute, Team S12, Inserm-UPMC Research Center 968.


Scientific Advisory Board

www.ophtimalia-medical.com [cached]

Prof. Christophe Baudouin
Prof. Christophe Baudouin, MD, phD Professor and Chair of Ophthalmology, Quinze-Vingts National Ophthalmology Hospital Research Director, Team 8, Chemokines and Glaucoma, Vision Institute, INSERM UMRS 968, University Paris 6


Novagali Pharma - Scientific Advisory Board

www.novagali.com [cached]

Headed by Professor Christophe Baudouin, Novagali's Scientific Advisory Board is composed of:
Professor Christophe Baudouin Professor Christophe Baudouin Chairman of the Scientific Advisory Board Professor of Ophthalmology at Quinze-Vingts National Ophthalmology Hospital (Paris, France) INSERM unit U598 (University Paris V, France)


Mednet - CME, CHE | Modifying the Risk of Glaucoma Progression

www.mednet.ca [cached]

Subclinical inflammation may also lead to surgical failure when attempts are made to correct glaucoma surgically, as noted by Dr. Christophe Baudouin, Professor of Ophthalmology, Quinze-Vingts National Ophthalmology Hospital, Paris, France.
The most obvious manifestations to BAK are allergic reactions seen after initial exposure. Not uncommonly, patients can develop a toxic reaction to preservative-containing products many months and even years after initiating treatment so symptoms may occur relatively distant to initial use, Dr. Baudouin noted. Laboratory studies have also confirmed that it is largely BAK and not the active ingredient in the medication that is associated with dose-dependent toxicity. In a comparison of preservative-containing vs. preservative-free beta blocking eye drops, Dr. Baudouin and colleagues found that all palpebral, conjunctival and corneal symptoms were significantly more frequent (PDr. Baudouin also emphasized that claims suggesting preservatives facilitate penetration of the drug into the eye are not supported by efficacy data, as there is no indication from clinical studies to date that preservative-free topical medications are any less effective at lowering IOP than those which contain a preservative.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory